“Cannabidiol has been reported to act as an antagonist of cannabinoid agonists at type 1 cannabinoid receptors (CB1 ).
We hypothesized that cannabidiol can inhibit cannabinoid agonist activity through negative allosteric modulation of CB1…
Cannabidiol behaved as a non-competitive negative allosteric modulator of CB1 .
Allosteric modulation, in conjunction with non-CB1 effects, may explain the in vivo effects of cannabidiol.
Allosteric modulators of CB1 have the potential to treat central nervous system and peripheral disorders while avoiding the adverse effects associated with orthosteric agonism or antagonism of CB1.”